Oncolytic measles virus strains as novel anticancer agents

Pavlos Msaouel, Mateusz Opyrchal, Evidio Domingo Musibay, Evanthia Galanis

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Introduction: Replication-competent oncolytic measles virus (MV) strains preferentially infect and destroy a wide variety of cancer tissues. Clinical translation of engineered attenuated MV vaccine derivatives is demonstrating the therapeutic potential and negligible pathogenicity of these strains in humans. Areas covered: The present review summarizes the mechanisms of MV tumor selectivity and cytopathic activity as well as the current data on the oncolytic efficacy and preclinical testing of MV strains. Investigational strategies to reprogram MV selectivity, escape antiviral immunity and modulate the immune system to enhance viral delivery and tumor oncolysis are also discussed. Expert opinion: Clinical viral kinetic data derived from noninvasive monitoring of reporter transgene expression will guide future protocols to enhance oncolytic MV efficacy. Anti-measles immunity is a major challenge of measles-based therapeutics and various strategies are being investigated to modulate immunity. These include the combination of MV therapy with immunosuppressive drugs, such as cyclophosphamide, the use of cell carriers and the introduction of immunomodulatory transgenes and wild-type virulence genes. Available MV retargeting technologies can address safety considerations that may arise as more potent oncolytic MV vectors are being developed.

Original languageEnglish (US)
Pages (from-to)483-502
Number of pages20
JournalExpert Opinion on Biological Therapy
Volume13
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Oncolytic Viruses
Measles virus
Viruses
Antineoplastic Agents
Immunity
Measles
Transgenes
Virulence
Tumors
Measles Vaccine
Neoplasms
Attenuated Vaccines
Immune system
Expert Testimony
Immunosuppressive Agents
Cyclophosphamide
Antiviral Agents
Immune System
Therapeutics
Vaccines

Keywords

  • Cancer gene therapy
  • Cell carriers
  • Measles virus
  • MV-NIS
  • Oncolytic virotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Oncolytic measles virus strains as novel anticancer agents. / Msaouel, Pavlos; Opyrchal, Mateusz; Domingo Musibay, Evidio; Galanis, Evanthia.

In: Expert Opinion on Biological Therapy, Vol. 13, No. 4, 04.2013, p. 483-502.

Research output: Contribution to journalArticle

Msaouel, Pavlos ; Opyrchal, Mateusz ; Domingo Musibay, Evidio ; Galanis, Evanthia. / Oncolytic measles virus strains as novel anticancer agents. In: Expert Opinion on Biological Therapy. 2013 ; Vol. 13, No. 4. pp. 483-502.
@article{191bfddeb0de48a88aad9ea6dd4fc2a2,
title = "Oncolytic measles virus strains as novel anticancer agents",
abstract = "Introduction: Replication-competent oncolytic measles virus (MV) strains preferentially infect and destroy a wide variety of cancer tissues. Clinical translation of engineered attenuated MV vaccine derivatives is demonstrating the therapeutic potential and negligible pathogenicity of these strains in humans. Areas covered: The present review summarizes the mechanisms of MV tumor selectivity and cytopathic activity as well as the current data on the oncolytic efficacy and preclinical testing of MV strains. Investigational strategies to reprogram MV selectivity, escape antiviral immunity and modulate the immune system to enhance viral delivery and tumor oncolysis are also discussed. Expert opinion: Clinical viral kinetic data derived from noninvasive monitoring of reporter transgene expression will guide future protocols to enhance oncolytic MV efficacy. Anti-measles immunity is a major challenge of measles-based therapeutics and various strategies are being investigated to modulate immunity. These include the combination of MV therapy with immunosuppressive drugs, such as cyclophosphamide, the use of cell carriers and the introduction of immunomodulatory transgenes and wild-type virulence genes. Available MV retargeting technologies can address safety considerations that may arise as more potent oncolytic MV vectors are being developed.",
keywords = "Cancer gene therapy, Cell carriers, Measles virus, MV-NIS, Oncolytic virotherapy",
author = "Pavlos Msaouel and Mateusz Opyrchal and {Domingo Musibay}, Evidio and Evanthia Galanis",
year = "2013",
month = "4",
doi = "10.1517/14712598.2013.749851",
language = "English (US)",
volume = "13",
pages = "483--502",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Oncolytic measles virus strains as novel anticancer agents

AU - Msaouel, Pavlos

AU - Opyrchal, Mateusz

AU - Domingo Musibay, Evidio

AU - Galanis, Evanthia

PY - 2013/4

Y1 - 2013/4

N2 - Introduction: Replication-competent oncolytic measles virus (MV) strains preferentially infect and destroy a wide variety of cancer tissues. Clinical translation of engineered attenuated MV vaccine derivatives is demonstrating the therapeutic potential and negligible pathogenicity of these strains in humans. Areas covered: The present review summarizes the mechanisms of MV tumor selectivity and cytopathic activity as well as the current data on the oncolytic efficacy and preclinical testing of MV strains. Investigational strategies to reprogram MV selectivity, escape antiviral immunity and modulate the immune system to enhance viral delivery and tumor oncolysis are also discussed. Expert opinion: Clinical viral kinetic data derived from noninvasive monitoring of reporter transgene expression will guide future protocols to enhance oncolytic MV efficacy. Anti-measles immunity is a major challenge of measles-based therapeutics and various strategies are being investigated to modulate immunity. These include the combination of MV therapy with immunosuppressive drugs, such as cyclophosphamide, the use of cell carriers and the introduction of immunomodulatory transgenes and wild-type virulence genes. Available MV retargeting technologies can address safety considerations that may arise as more potent oncolytic MV vectors are being developed.

AB - Introduction: Replication-competent oncolytic measles virus (MV) strains preferentially infect and destroy a wide variety of cancer tissues. Clinical translation of engineered attenuated MV vaccine derivatives is demonstrating the therapeutic potential and negligible pathogenicity of these strains in humans. Areas covered: The present review summarizes the mechanisms of MV tumor selectivity and cytopathic activity as well as the current data on the oncolytic efficacy and preclinical testing of MV strains. Investigational strategies to reprogram MV selectivity, escape antiviral immunity and modulate the immune system to enhance viral delivery and tumor oncolysis are also discussed. Expert opinion: Clinical viral kinetic data derived from noninvasive monitoring of reporter transgene expression will guide future protocols to enhance oncolytic MV efficacy. Anti-measles immunity is a major challenge of measles-based therapeutics and various strategies are being investigated to modulate immunity. These include the combination of MV therapy with immunosuppressive drugs, such as cyclophosphamide, the use of cell carriers and the introduction of immunomodulatory transgenes and wild-type virulence genes. Available MV retargeting technologies can address safety considerations that may arise as more potent oncolytic MV vectors are being developed.

KW - Cancer gene therapy

KW - Cell carriers

KW - Measles virus

KW - MV-NIS

KW - Oncolytic virotherapy

UR - http://www.scopus.com/inward/record.url?scp=84879583055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879583055&partnerID=8YFLogxK

U2 - 10.1517/14712598.2013.749851

DO - 10.1517/14712598.2013.749851

M3 - Article

C2 - 23289598

AN - SCOPUS:84879583055

VL - 13

SP - 483

EP - 502

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 4

ER -